Key takeaway: During the Q1 FY27 earnings conference call, management reported a revenue of Rs. 666 crore, reflecting a year-on-year growth of 19.22%, driven by strong demand in both domestic and international markets. The company emphasized its focus on executing expansion projects and enhancing its specialty product portfolio. Management highlighted the stability of its supply chain despite global geopolitical challenges and noted the ongoing progress in its joint venture, PRIGIV. The CFO, Narayan S. Iyer, shared that EBITDA margins remained consistent at around 25% over the last nine quarters, with a net profit of Rs. 83.2 crore for the quarter. The company is also advancing its merger plans to streamline operations and enhance scalability. Management set a goal of achieving Rs. 5,000 crore in revenue and over Rs. 1,000 crore in EBITDA over the next three to four years, indicating a commitment to sustainable growth.

Key takeaway: The investor presentation for Privi Speciality Chemicals Limited reported a strong start to Q1 FY27, with total income of Rs 681.42 crore, reflecting a 20.01% year-on-year growth. EBITDA reached Rs 167.47 crore, marking an 18.73% increase, while net profit was Rs 84.21 crore, up 35.97% year-on-year. Management noted broad-based demand across domestic and export markets, despite a fire incident at a warehouse that resulted in a loss of Rs 2.78 crore, for which an insurance claim has been filed. The company emphasized its resilience amid global headwinds and highlighted ongoing expansion projects, which are on track for completion in the second half of 2028. The presentation also outlined a strategic vision aiming for Rs 5,000 crore in revenue and over Rs 1,000 crore in EBITDA by FY29-30, driven by operational efficiency and an enhanced product mix.

Key takeaway: During the earnings conference call held on May 12, 2026, management discussed Privi Speciality Chemicals Limited's strong performance for FY26, highlighting a 22% revenue growth year-on-year and consistent EBITDA margins above 25%. The company reported a total income of INR 2,582.92 crore for the year, with a profit after tax of INR 327.54 crore, reflecting a 75.16% increase from the previous year. Management emphasized the successful execution of operational efficiencies and a focus on expanding their specialty chemicals portfolio. They noted that the joint venture with PRIGIV turned profitable for the first time in Q4 FY26. Additionally, management mentioned ongoing capex plans to enhance production capacity and the anticipated merger with Privi Fine Sciences and Privi Biotechnologies, which aims to streamline operations. The call concluded with management expressing confidence in sustaining growth and profitability moving forward.

Key takeaway: The investor presentation by Privi Speciality Chemicals Limited for the quarter and year ended March 31, 2026, reported a total income of ₹2,583 crore, reflecting a 22% year-on-year increase. Management highlighted strong execution across the business, with operating cash flow of ₹550 crore and a reduction in total debt by ₹113 crore. The presentation detailed a consolidated profit after tax (PAT) of ₹327.54 crore for FY26, a 75.2% increase year-on-year. Management emphasized the company's focus on sustainability and responsible manufacturing, with 70% of raw materials derived from renewable resources. The presentation outlined a growth strategy aiming for ₹5,000 crore in revenue and over ₹1,000 crore in EBITDA by FY29-30, supported by new product innovations and capacity expansions. The company also noted its commitment to sustainability goals, including significant reductions in greenhouse gas emissions and waste management initiatives.

Key takeaway: The earnings conference call for Privi Speciality Chemicals Limited, held on February 10, 2026, highlighted the company's resilient performance despite global challenges. Management reported a 24% revenue growth for both the third quarter and the nine-month period ended December 31, 2025. EBITDA margins exceeded 25% for the past three quarters, attributed to operational efficiencies and a diversified product mix. Management outlined a three-phase expansion plan aimed at increasing capacity by 55% and enhancing the specialty products portfolio. The joint venture with Givaudan, Prigiv, was noted to be progressing well, achieving positive EBITDA. Financial highlights included a total income of INR 611.15 crores for Q3 and INR 1,857 crores for the nine-month period, with a profit after tax of INR 74.85 crores for Q3. Management emphasized a commitment to maintaining healthy margins and outlined plans for future growth, including new product development and capacity expansion.

Key takeaway: Privi Speciality Chemicals Limited reported a 24% year-over-year revenue growth for Q3 and the first nine months of FY25-26, reaching Rs. 611.15 crore and Rs. 1,857.23 crore, respectively. EBITDA increased by 37% to Rs. 157.85 crore, while PAT surged by 76% to Rs. 77.99 crore in Q3. The company attributed its performance to a diversified product mix and operational efficiencies, despite challenges from global tariff uncertainties. Management highlighted a commitment to a strategic growth roadmap, including a proposed Scheme of Amalgamation aimed at operational consolidation. The presentation also emphasized ongoing investments in capacity expansion and innovation in green chemistry and biotechnology. Key recognitions included awards for export excellence and sustainability. The company is on track with its capacity augmentation projects and aims to achieve its long-term vision of Rs. 5,000 crore in revenue and Rs. 1,000 crore in EBITDA over the next 3-4 years.